JP2002053555A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002053555A5 JP2002053555A5 JP2001164523A JP2001164523A JP2002053555A5 JP 2002053555 A5 JP2002053555 A5 JP 2002053555A5 JP 2001164523 A JP2001164523 A JP 2001164523A JP 2001164523 A JP2001164523 A JP 2001164523A JP 2002053555 A5 JP2002053555 A5 JP 2002053555A5
- Authority
- JP
- Japan
- Prior art keywords
- ethyl
- adamantyl
- pyridyl
- propyl
- urea
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- -1 1-adamantyl Chemical group 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- MHBZVASHZYXXNB-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-1-pentyl-3-(4-pyridin-4-ylbutan-2-yl)urea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCCCC)C(=O)NC(C)CCC1=CC=NC=C1 MHBZVASHZYXXNB-UHFFFAOYSA-N 0.000 description 1
- YWJSTJKZGMYFRH-AATRIKPKSA-N 1-[2-(1-adamantyl)ethyl]-1-pentyl-3-[(e)-3-pyridin-4-ylprop-2-enyl]urea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCCCC)C(=O)NC\C=C\C1=CC=NC=C1 YWJSTJKZGMYFRH-AATRIKPKSA-N 0.000 description 1
- YWJSTJKZGMYFRH-WAYWQWQTSA-N 1-[2-(1-adamantyl)ethyl]-1-pentyl-3-[(z)-3-pyridin-4-ylprop-2-enyl]urea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCCCC)C(=O)NC\C=C/C1=CC=NC=C1 YWJSTJKZGMYFRH-WAYWQWQTSA-N 0.000 description 1
- QDYISHPTUNJPHS-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-3-(2-methyl-3-pyridin-4-ylpropyl)-1-pentylurea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCCCC)C(=O)NCC(C)CC1=CC=NC=C1 QDYISHPTUNJPHS-UHFFFAOYSA-N 0.000 description 1
- KLVNJZLUOJMGAR-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-3-(3-pyridin-4-ylpropyl)-1-(3,3,3-trifluoropropyl)urea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCC(F)(F)F)C(=O)NCCCC1=CC=NC=C1 KLVNJZLUOJMGAR-UHFFFAOYSA-N 0.000 description 1
- MGONZICZEFZNQG-UHFFFAOYSA-N 1-[3-(1-adamantyl)propyl]-1-propyl-3-(3-pyridin-4-ylpropyl)urea Chemical compound C1C(C2)CC(C3)CC2CC13CCCN(CCC)C(=O)NCCCC1=CC=NC=C1 MGONZICZEFZNQG-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 0 CC(C)(C)OC(N(C)C*)=O Chemical compound CC(C)(C)OC(N(C)C*)=O 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- QVHCDIXOASJMAN-UHFFFAOYSA-N n-[2-(1-adamantyl)ethyl]pentan-1-amine Chemical compound C1C(C2)CC3CC2CC1(CCNCCCCC)C3 QVHCDIXOASJMAN-UHFFFAOYSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001164523A JP3867196B2 (ja) | 2000-05-31 | 2001-05-31 | ＴＮＦ−α産生阻害物質 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000162945 | 2000-05-31 | ||
| JP2000-162945 | 2000-05-31 | ||
| JP2001164523A JP3867196B2 (ja) | 2000-05-31 | 2001-05-31 | ＴＮＦ−α産生阻害物質 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006140241A Division JP4482735B2 (ja) | 2000-05-31 | 2006-05-19 | ＴＮＦ−α産生阻害物質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002053555A JP2002053555A (ja) | 2002-02-19 |
| JP2002053555A5 true JP2002053555A5 (enExample) | 2006-07-20 |
| JP3867196B2 JP3867196B2 (ja) | 2007-01-10 |
Family
ID=18666780
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001164523A Expired - Fee Related JP3867196B2 (ja) | 2000-05-31 | 2001-05-31 | ＴＮＦ−α産生阻害物質 |
| JP2006140241A Expired - Fee Related JP4482735B2 (ja) | 2000-05-31 | 2006-05-19 | ＴＮＦ−α産生阻害物質 |
| JP2009283085A Pending JP2010059205A (ja) | 2000-05-31 | 2009-12-14 | ＴＮＦ−α産生阻害物質 |
| JP2009283084A Pending JP2010059204A (ja) | 2000-05-31 | 2009-12-14 | ＴＮＦ−α産生阻害物質 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006140241A Expired - Fee Related JP4482735B2 (ja) | 2000-05-31 | 2006-05-19 | ＴＮＦ−α産生阻害物質 |
| JP2009283085A Pending JP2010059205A (ja) | 2000-05-31 | 2009-12-14 | ＴＮＦ−α産生阻害物質 |
| JP2009283084A Pending JP2010059204A (ja) | 2000-05-31 | 2009-12-14 | ＴＮＦ−α産生阻害物質 |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US7098226B2 (enExample) |
| EP (4) | EP1743885B1 (enExample) |
| JP (4) | JP3867196B2 (enExample) |
| KR (2) | KR100880698B1 (enExample) |
| CN (3) | CN1284771C (enExample) |
| AT (4) | ATE448204T1 (enExample) |
| AU (3) | AU2001260674B2 (enExample) |
| CA (2) | CA2736344A1 (enExample) |
| CY (1) | CY1107089T1 (enExample) |
| DE (4) | DE60127595T2 (enExample) |
| DK (1) | DK1302461T3 (enExample) |
| ES (4) | ES2353020T3 (enExample) |
| NO (2) | NO324472B1 (enExample) |
| PT (1) | PT1302461E (enExample) |
| WO (1) | WO2001092229A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1743885B1 (en) * | 2000-05-31 | 2009-11-11 | Santen Pharmaceutical Co., Ltd. | 1-[(adamantyl)alkyl]-3-[(pyridinyl)alkyl]urea compounds as TNF-.alpha inhibitors useful for autoimmune diseases |
| AU2002349621A1 (en) * | 2001-11-30 | 2003-06-10 | Santen Pharmaceutical Co., Ltd. | Angiogenesis inhibitor |
| JP3813152B2 (ja) | 2002-03-12 | 2006-08-23 | メルク エンド カムパニー インコーポレーテッド | 置換アミド類 |
| CN101404986B (zh) | 2002-05-17 | 2011-09-28 | 赛奎拉公司 | 用于诊断和治疗感染性疾病的组合物和制药方法 |
| US20040033986A1 (en) | 2002-05-17 | 2004-02-19 | Protopopova Marina Nikolaevna | Anti tubercular drug: compositions and methods |
| US7456222B2 (en) | 2002-05-17 | 2008-11-25 | Sequella, Inc. | Anti tubercular drug: compositions and methods |
| WO2005034857A2 (en) | 2003-09-05 | 2005-04-21 | Sequella, Inc. | Methods and compositions comprising diamines as new anti-tubercular therapeutics |
| WO2005102332A1 (ja) * | 2004-04-27 | 2005-11-03 | Santen Pharmaceutical Co., Ltd. | 変形性関節症治療剤 |
| WO2005102331A1 (ja) * | 2004-04-27 | 2005-11-03 | Santen Pharmaceutical Co., Ltd. | 骨粗鬆症治療剤 |
| UA87854C2 (en) * | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
| WO2006035760A1 (ja) * | 2004-09-27 | 2006-04-06 | Santen Pharmaceutical Co., Ltd. | 皮膚疾患治療剤 |
| WO2006035759A1 (ja) * | 2004-09-27 | 2006-04-06 | Santen Pharmaceutical Co., Ltd. | 呼吸器疾患治療剤 |
| WO2006043518A1 (ja) * | 2004-10-18 | 2006-04-27 | Santen Pharmaceutical Co., Ltd. | 神経疾患治療剤 |
| US20090192198A1 (en) | 2005-01-05 | 2009-07-30 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
| EP2835367A1 (en) * | 2005-01-05 | 2015-02-11 | AbbVie Inc. | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
| CN103242192B (zh) * | 2005-01-05 | 2016-05-04 | Abbvie公司 | 11-β-羟甾类脱氢酶1型酶的抑制剂 |
| US8562629B2 (en) * | 2006-10-24 | 2013-10-22 | Arthrocare Corporation | Suture device having selective needle actuation and related method |
| EP1935420A1 (en) | 2006-12-21 | 2008-06-25 | Merck Sante | 2-Adamantyl-butyramide derivatives as selective 11beta-HSD1 inhibitors |
| WO2009020603A2 (en) * | 2007-08-08 | 2009-02-12 | The Scripps Research Institute | Upp amphiphilic alpha-helix mimetics |
| CA2702455A1 (en) | 2007-10-16 | 2009-04-23 | Santen Pharmaceutical Co., Ltd. | Therapeutic agent for trpv1-mediated disease |
| US8686006B2 (en) * | 2008-10-22 | 2014-04-01 | Santen Pharmaceutical Co., Ltd. | Pharmaceutical composition for improving intestinal absorption |
| RU2404157C1 (ru) * | 2009-02-16 | 2010-11-20 | Государственное образовательное учреждение высшего профессионального образования Волгоградский государственный технический университет (ВолгГТУ) | Способ получения n-(1-адамантилалкил)циклоалкиламинов |
| HRP20090186A2 (hr) | 2009-03-31 | 2010-10-31 | Institut Ruđer Bošković | Adamantanski bisureidni derivati, metoda priprave i primjena u detekciji aniona |
| US8357939B2 (en) * | 2009-12-29 | 2013-01-22 | Siltronic Ag | Silicon wafer and production method therefor |
| JP6744218B2 (ja) | 2013-11-15 | 2020-08-19 | ザ ウィスター インスティテュート オブ アナトミー アンド バイオロジー | Ｅｂｎａ１阻害剤およびそれらの使用方法 |
| BR112017024481B1 (pt) | 2015-05-14 | 2020-11-17 | The Wistar Institute Of Anatomy And Biology | composto inibidor de ebna1, composição farmacêutica compreendendo dito composto e usos terapêuticos do mesmo |
| CN112543634A (zh) | 2018-05-17 | 2021-03-23 | 威斯达研究所 | Ebna1抑制剂晶体形式及其制备和使用方法 |
| CN110423216B (zh) * | 2019-08-26 | 2021-01-05 | 浙江工业大学 | 一种2-(1-金刚烷甲酰胺基)乙基甲酸酯类化合物及其制备方法和应用 |
| KR20250091282A (ko) * | 2022-10-21 | 2025-06-20 | 이더알엔에이 이뮤노테라피스 엔브이 | 이온화 가능 지질 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2640055A (en) * | 1951-01-06 | 1953-05-26 | Warner Hudnut Inc | Amides |
| CH500979A (de) * | 1967-02-16 | 1970-12-31 | Shimamoto Takio | Verfahren zur Herstellung von Pyridinmethylcarbamaten |
| US3682922A (en) | 1969-01-16 | 1972-08-08 | Searle & Co | N-acyl-n-{8 (n{40 ,n{40 -disubstituted amino)-alkyl{9 -1-adamantylmethylamines |
| US4597902A (en) | 1981-05-20 | 1986-07-01 | A. H. Robins Company, Incorporated | N-(arylthioalkyl)-N'-(aminoalkyl)ureas |
| US4724235A (en) | 1981-05-20 | 1988-02-09 | A. H. Robins Company, Incorporated | N-(arylthioalkyl)-N'-(aminoalkyl)ureas useful in the treatment of arrhythmia |
| US4555515A (en) * | 1985-02-25 | 1985-11-26 | Stauffer Chemical Co. | Pyridylpropyl carbamates as insect repellents |
| US5599944A (en) * | 1987-03-24 | 1997-02-04 | Bayer Aktiengesellschaft | Intermediates for herbicidal sulphonylaminocarbonyltriazolinones having substituents which are bonded via sulphur |
| US5776963A (en) * | 1989-05-19 | 1998-07-07 | Hoechst Marion Roussel, Inc. | 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility |
| FR2664269B1 (fr) | 1990-07-05 | 1992-10-02 | Roussel Uclaf | Nouveaux derives n-substitues d'alpha-mercapto alkylamines, leur procede de preparation, leur application a titre de medicaments et les compositions les renfermant. |
| US5173506A (en) | 1990-08-16 | 1992-12-22 | Schering Corporation | N-(mercaptoalkyl)ureas and carbamates |
| EP0557408A4 (en) | 1990-11-06 | 1993-10-27 | Smith-Kline Beecham Corporation | Imidazolidinone compounds |
| NZ242054A (en) * | 1991-03-22 | 1993-11-25 | British Tech Group | Pyridine derivatives having a bridged alicyclic group; medicaments |
| GB9401129D0 (en) | 1994-01-21 | 1994-03-16 | British Bio Technology | Hydroxamic acid derivatives as metalloproteinase inhibitors |
| DE69533284T2 (de) * | 1994-04-29 | 2005-07-21 | Pfizer Inc. | Neue cyclische und acyclische amide zur erhöhung der neurotransmitter ausschüttung |
| EP1304322A3 (en) | 1995-08-22 | 2003-11-19 | Japan Tobacco Inc. | Carboxylic acid compound and use thereof |
| GB9526558D0 (en) * | 1995-12-27 | 1996-02-28 | Fujisawa Pharmaceutical Co | Heterobicyclic derivatives |
| GB9526560D0 (en) * | 1995-12-27 | 1996-02-28 | Bayer Ag | Use of 2-Amino-Heterocycles |
| WO1997026250A1 (en) * | 1996-01-16 | 1997-07-24 | Merck & Co., Inc. | Integrin receptor antagonists |
| IT1283637B1 (it) | 1996-05-14 | 1998-04-23 | Italfarmaco Spa | Composti ad attivita' antinfiammatoria ed immunosoppressiva |
| WO1998027069A1 (en) | 1996-12-17 | 1998-06-25 | Fujisawa Pharmaceutical Co., Ltd. | Piperazine compounds as inhibitors of mmp or tnf |
| DE59806420D1 (de) | 1997-09-17 | 2003-01-09 | Chemiefaser Lenzing Ag | Verfahren zur Behandlung von Cellulosefasern |
| EP0903434B1 (de) | 1997-09-17 | 2002-11-27 | Lenzing Aktiengesellschaft | Verfahren zur Behandlung von Cellulosefasern |
| KR100589474B1 (ko) | 1998-03-26 | 2006-06-14 | 산텐 세이야꾸 가부시키가이샤 | 신규한 우레아 유도체 |
| JP3603177B2 (ja) | 1998-03-26 | 2004-12-22 | 参天製薬株式会社 | 新規ウレア誘導体 |
| KR100663143B1 (ko) | 1998-08-05 | 2007-01-02 | 산텐 세이야꾸 가부시키가이샤 | 질소 포함 방향족 헤테로고리를 갖는 신규 우레아 유도체 |
| JP3472917B2 (ja) | 1998-08-05 | 2003-12-02 | 参天製薬株式会社 | 含窒素芳香族複素環を有する新規ウレア誘導体 |
| EP1165531A1 (en) * | 1999-03-19 | 2002-01-02 | Du Pont Pharmaceuticals Company | N-adamant-1-yl-n'- 4-chlorobenzothiazol-2-yl] urea useful in the treatment of inflammation and as an anticancer radiosensitizing agent |
| KR20010112408A (ko) * | 1999-04-07 | 2001-12-20 | 모리타 다카카즈 | Ｎ-치환되고-Ｎ'-치환된 우레아 유도체 및 ＴＮＦ-α 생성억제제로서의 그의 용도 |
| DE29910780U1 (de) * | 1999-06-21 | 1999-09-16 | Hahn Schickard Ges | Halte- und Betätigungsvorrichtung |
| EP1743885B1 (en) * | 2000-05-31 | 2009-11-11 | Santen Pharmaceutical Co., Ltd. | 1-[(adamantyl)alkyl]-3-[(pyridinyl)alkyl]urea compounds as TNF-.alpha inhibitors useful for autoimmune diseases |
| AU2002349621A1 (en) | 2001-11-30 | 2003-06-10 | Santen Pharmaceutical Co., Ltd. | Angiogenesis inhibitor |
-
2001
- 2001-05-31 EP EP06076696A patent/EP1743885B1/en not_active Expired - Lifetime
- 2001-05-31 JP JP2001164523A patent/JP3867196B2/ja not_active Expired - Fee Related
- 2001-05-31 AU AU2001260674A patent/AU2001260674B2/en not_active Ceased
- 2001-05-31 US US10/168,777 patent/US7098226B2/en not_active Expired - Fee Related
- 2001-05-31 ES ES05290274T patent/ES2353020T3/es not_active Expired - Lifetime
- 2001-05-31 DE DE60127595T patent/DE60127595T2/de not_active Expired - Lifetime
- 2001-05-31 ES ES01934447T patent/ES2293993T3/es not_active Expired - Lifetime
- 2001-05-31 CA CA2736344A patent/CA2736344A1/en not_active Abandoned
- 2001-05-31 PT PT01934447T patent/PT1302461E/pt unknown
- 2001-05-31 AT AT06076696T patent/ATE448204T1/de not_active IP Right Cessation
- 2001-05-31 AU AU6067401A patent/AU6067401A/xx active Pending
- 2001-05-31 CN CNB018102336A patent/CN1284771C/zh not_active Expired - Fee Related
- 2001-05-31 DE DE60130658T patent/DE60130658T2/de not_active Expired - Lifetime
- 2001-05-31 ES ES06076696T patent/ES2339141T3/es not_active Expired - Lifetime
- 2001-05-31 EP EP05290275A patent/EP1561749B1/en not_active Expired - Lifetime
- 2001-05-31 CN CNB2004100546746A patent/CN1307159C/zh not_active Expired - Fee Related
- 2001-05-31 KR KR1020027016230A patent/KR100880698B1/ko not_active Expired - Fee Related
- 2001-05-31 AT AT05290275T patent/ATE358122T1/de not_active IP Right Cessation
- 2001-05-31 WO PCT/JP2001/004586 patent/WO2001092229A1/ja not_active Ceased
- 2001-05-31 AT AT01934447T patent/ATE374186T1/de active
- 2001-05-31 AT AT05290274T patent/ATE481385T1/de not_active IP Right Cessation
- 2001-05-31 DE DE60140495T patent/DE60140495D1/de not_active Expired - Lifetime
- 2001-05-31 DE DE60143098T patent/DE60143098D1/de not_active Expired - Lifetime
- 2001-05-31 EP EP05290274A patent/EP1568692B1/en not_active Expired - Lifetime
- 2001-05-31 CN CNB200410054677XA patent/CN1324012C/zh not_active Expired - Fee Related
- 2001-05-31 DK DK01934447T patent/DK1302461T3/da active
- 2001-05-31 CA CA2409741A patent/CA2409741C/en not_active Expired - Fee Related
- 2001-05-31 KR KR1020087023872A patent/KR100978304B1/ko not_active Expired - Fee Related
- 2001-05-31 ES ES05290275T patent/ES2284138T3/es not_active Expired - Lifetime
- 2001-05-31 EP EP01934447A patent/EP1302461B1/en not_active Expired - Lifetime
-
2002
- 2002-11-28 NO NO20025718A patent/NO324472B1/no not_active IP Right Cessation
-
2006
- 2006-02-28 AU AU2006200864A patent/AU2006200864B2/en not_active Ceased
- 2006-05-19 JP JP2006140241A patent/JP4482735B2/ja not_active Expired - Fee Related
- 2006-06-07 US US11/448,634 patent/US7491739B2/en not_active Expired - Fee Related
- 2006-06-22 US US11/472,603 patent/US7345064B2/en not_active Expired - Fee Related
-
2007
- 2007-06-29 NO NO20073371A patent/NO20073371L/no not_active Application Discontinuation
- 2007-08-15 US US11/893,238 patent/US20080182881A1/en not_active Abandoned
- 2007-12-14 CY CY20071101588T patent/CY1107089T1/el unknown
-
2009
- 2009-09-23 US US12/586,515 patent/US7923461B2/en not_active Expired - Fee Related
- 2009-12-14 JP JP2009283085A patent/JP2010059205A/ja active Pending
- 2009-12-14 JP JP2009283084A patent/JP2010059204A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002053555A5 (enExample) | ||
| CN1878757A (zh) | 吡啶酮衍生物及其应用 | |
| JP2005501120A5 (enExample) | ||
| JP2004512328A5 (enExample) | ||
| JP2006514626A5 (enExample) | ||
| JP2007016035A5 (enExample) | ||
| WO2001062737A3 (en) | Amino pyrazole derivatives useful for the treatment of obesity and other disorders | |
| JP2006526031A5 (enExample) | ||
| IL181697A0 (en) | Medicinal composition | |
| JO2371B1 (en) | 4-phenyl-pyridine derivatives | |
| NO20071577L (no) | Bifenyloksyiddiksyrederivater for behandling av luftveissykdommer | |
| JP2004506632A5 (enExample) | ||
| JP2004532209A5 (enExample) | ||
| JP2010502664A5 (enExample) | ||
| JPH1036346A5 (enExample) | ||
| JP2005526081A5 (ja) | 代謝型グルタメート受容体−５の二アリール置換テトラゾールモジュレータ | |
| WO2002015662A3 (en) | Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists | |
| EP1498411A4 (en) | DICETOHYDRAZINE DERIVATIVE COMPOUNDS AND MEDICAMENTS CONTAINING THESE COMPOUNDS AS ACTIVE INGREDIENTS | |
| ATE556061T1 (de) | Therapeutisches oder prophylaktisches mittel gegen multiple sklerose | |
| JP2006517939A5 (enExample) | ||
| WO2001074791A1 (en) | Diazepane derivatives or salts thereof | |
| JP2010511631A5 (enExample) | ||
| JP2010527993A5 (enExample) | ||
| JP2002030084A5 (enExample) | ||
| JP2004532828A5 (enExample) |